Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo
ReutersJan 11, 2026 10:16 PM
Jan 11 (Reuters) - Royalty Pharma PLC RPRX.O:
TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCELERATE DEVELOPMENT OF POTENTIAL TREATMENT FOR VITILIGO
TEVA - TEVA TO SHARE TEV-'408 TRIAL RESULTS IN 2026
ROYALTY PHARMA - TO PROVIDE UP TO $500 MILLION FOR TEVA'S TEV-'408
ROYALTY PHARMA : TEV-'408 IS CURRENTLY IN PHASE 1B FOR TREATMENT OF VITILIGO AND IN PHASE 2A FOR CELIAC DISEASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
The Tether Hegemony: Record Valuations and the Internalization of Crypto’s Infrastructure
Tether (USDT) has not only shattered valuation records but has also embarked on a radical restructuring of its investment portfolio, evolving into a hybrid stablecoin issuer, venture capitalist, and infrastructure operator.TradingKey
Fri, Jan 9
Tesla 2026: Deep Tech Breakthroughs Finally Move the Needle on Earnings
If 2025 was a turbulent year for Tesla, characterized by speculative valuation promises, then with the realization of commercial commitments such as the mass production of Cybercab and Optimus, 2026 could be a year for Tesla to consolidate its technological advancements and return to fundamentals.TradingKey
Thu, Jan 8
Dogecoin Price Prediction: 2025 Maximum Drawdown Over 70%, 2026 DOGE Will Hit $1 Mark?
Overall, Dogecoin's future remains highly uncertain. While it showed strong rebound momentum in early 2026, its price gains primarily depend on community consensus and market sentiment due to a lack of technical and ecosystem support. Should Bitcoin reach new highs again, DOGE might follow suit. HowTradingKey
Tue, Jan 6
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
